EGFR and ovarian cancer: Several studies in other solid cancers (lung and ovarian cancers) have also indicated that STAT3 activation was associated with EGFR resistance and blocking both EGFR and JAK/STAT signalling pathways at different levels (JAK inhibitors AZD1480 or P6, or siRNA against JAK or STAT3) have shown synergistic therapeutic effects compared with EGFR inhibition alone [49, 50].